Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Maves vs MedLeanRx

Maves
Graded #89

Lower grade

vs+2.1000000000000085
MedLeanRx
Graded #66

Higher grade

The verdict

MedLeanRx takes it — 73.9/100 to 71.8/100.

MedLeanRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MedLeanRx is a physician-guided telehealth weight-loss clinic serving Texas only, based in Spring, TX.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMaves +10
84
74
Dose & formulationMedLeanRx +28
65
93
Clinical oversightMedLeanRx +1
76
77
Labs & monitoringEven
52
52
FulfillmentMaves +10
87
77
Contract termsEven
55
55
Maves · left barMedLeanRx · right bar

The numbers

MetricMavesMedLeanRx
WeighScore71.8/10073.9/100
GradeCC
Scorecard rank#89#66
Semaglutide$99/mo (starting dose, first-month rate, compounded)$149/mo (starting dose, promotional rate, compounded)
TirzepatideNot disclosed$269/mo (starting dose, compounded)
CoverageAll 50 states1 state
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
Maves

Graded #89 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed
MedLeanRx

Graded #66 · C

Strengths

  • Compounded semaglutide $149/mo in both weekly injection and daily oral tablet form
  • Brand pathway for Wegovy, Zepbound, and Foundayo (orforglipron) at a $99/mo fee plus medication cost
  • Intro bundle: 2 months of compounded tirzepatide (2 mg weekly) for $325 — about $163/mo
  • LegitScript seal displayed; named supervising physician (Dr. Johnson Uzor, MD)
  • Free shipping, no hidden fees, and cancel-anytime plans per homepage trust chips

Where it loses points

  • Texas only — not available in the other 49 states
  • Compounded tirzepatide is $269/mo at standard pricing, above the ~$249 market median
  • Strict no-refund policy: 'All sales are final' per Terms & Conditions
  • Pharmacy partner not publicly named — a transparency gap for a compounding service
  • Legal entity name and founding details not published on the site

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard